Cancer Liquid Biopsy Market Assessment

   Single User - $2,500
   Site License (one location, 10 users) - $3,750
   Corporate License - $5,000

Published Nov 8, 2017 | 91 Pages | Pub ID: KLI15527193

Cancer Liquid Biopsy Market Assessment

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy Contains Markets for the Following:

  • Breast Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Colorectal Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Lung Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Ovarian Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Pancreatic Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Other Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Top Ten Companies in the Liquid Biopsy Market

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging. Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.

Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy. Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA.

This report segments market by type of cancer and corresponding regional market. For segmentation by type of analyte and type of application, see Kalorama's larger study on Liquid Biopsy Markets.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.